{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:28:32Z","timestamp":1780050512511,"version":"3.53.1"},"reference-count":114,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. In addition, there may be a link between the use of thiopurines or anti-tumor necrosis factor drugs (anti-TNF) and these pathologies. The treatment of patients with Crohn\u2019s disease who have previously been diagnosed with lymphoma is a challenge for gastroenterologists. In this report, we examine important clinical issues related to the treatment of patients with inflammatory bowel disease with active lymphoma, as well as of patients with hematological cancer history. In this discussion, we take into account most of the available treatments for inflammatory bowel disease, as well as the impact of chronic inflammation and viral infections. In addition, we try to find common ground for the development of lymphoproliferative disorders and autoimmune diseases. Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. Chronic inflammatory processes and viral infections play an important role in carcinogenesis. In addition, there may be a link between the use of thiopurines or anti-TNF drugs and these pathologies. A significant risk of the development of lymphoma in people undergoing each therapy should be considered, and it should be estimated how much greater this risk will be in patients with a history of lymphoproliferative disorders. The following review is an attempt to answer which therapy would be the most appropriate for patients with Crohn\u2019s disease and a history of lymphoma treatment. A lack of clear guidelines creates great challenges for doctors.<\/jats:p>","DOI":"10.3390\/ijms25084241","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T09:37:31Z","timestamp":1712828251000},"page":"4241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9754-0130","authenticated-orcid":false,"given":"Katarzyna","family":"Stasik","sequence":"first","affiliation":[{"name":"Department of Gastroenterology with IBD Unit, Clinical Hospital No. 2, 35-301 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5954-151X","authenticated-orcid":false,"given":"Rafa\u0142","family":"Filip","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rzeszow, 35-959 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Masciopinto, P., Dell\u2019Olio, G., De Robertis, R., Specchia, G., Musto, P., and Albano, F. (2020). The Role of Autoimmune Diseases in the Prognosis of Lymphoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113403"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Dignass","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ajcp\/aqz078","article-title":"Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms","volume":"152","author":"Lim","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/aje\/kwi341","article-title":"Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin\u2019s lymphoma: A case-control study","volume":"162","author":"Engels","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","article-title":"Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","article-title":"Malignant lymphoma-associated autoimmune diseases\u2014A descriptive epidemiological study","volume":"22","author":"Gergely","year":"2002","journal-title":"Rheumatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622648","DOI":"10.3389\/fonc.2021.622648","article-title":"Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma","volume":"11","author":"Peifeng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/ccr3.3364","article-title":"An unusual case of diffuse large B-cell lymphoma complicating a Crohn\u2019s disease","volume":"8","author":"Sabbah","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12185-008-0068-5","article-title":"Primary non-Hodgkin lymphomas in the small and large intestine: Clinicopathological characteristics and management of 40 patients","volume":"87","author":"Li","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Laredo, V., Garc\u00eda-Mateo, S., Mart\u00ednez-Dom\u00ednguez, S.J., L\u00f3pez de la Cruz, J., Gargallo-Puyuelo, C.J., and Gomoll\u00f3n, F. (2023). Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. Cancers, 15.","DOI":"10.3390\/cancers15030871"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000509544","article-title":"Malignancies in Inflammatory Bowel Disease","volume":"101","author":"Greuter","year":"2020","journal-title":"Digestion"},{"key":"ref_17","first-page":"450","article-title":"Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study","volume":"26","author":"Biancone","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.22516\/25007440.202","article-title":"Enfermedad de Crohn y linfoma primario de intestino delgado: Reporte de caso","volume":"34","year":"2019","journal-title":"Rev. Colomb. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdn595","article-title":"Cancer risks in Crohn disease patients","volume":"20","author":"Hemminki","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000522044","article-title":"Primary Diffuse Large B-Cell Lymphoma of the Rectum in a Non-Immunosuppressed Patient with Ulcerative Colitis","volume":"30","author":"Saraiva","year":"2022","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_21","first-page":"1","article-title":"Crohn\u2019s Disease and Malignancies\u2014An Update","volume":"1","author":"Fornaro","year":"2017","journal-title":"J. Clin. Trials Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000455180","article-title":"Hodgkin\u2019s Lymphoma in Crohn\u2019s Disease Treated with Infliximab","volume":"24","author":"Carvalho","year":"2017","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the interlymph consortium","volume":"111","author":"Smedby","year":"2008","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fphar.2019.00247","article-title":"Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies","volume":"10","author":"Ferraro","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_30","first-page":"784","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"5","author":"Siegel","year":"2009","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: A population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3389\/fonc.2019.01198","article-title":"Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database","volume":"12","author":"Yin","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/ibd.21487","article-title":"Clinical course of Crohn\u2019s disease following treatment of lymphoma","volume":"17","author":"Mourabet","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":"Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children","volume":"96","author":"Oschlies","year":"2011","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"76793","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein\u2013Barr virus-associated T and natural killer cell lymphoma cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S693","DOI":"10.14309\/00000434-201210001-01710","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for ulcerative colitis: A nationwide 10-year retrospective cohort from the veterans affairs healthcare system","volume":"107","author":"Abbas","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ecco-jcc\/jjw048","article-title":"Inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case\u2013control IG-IBD study","volume":"10","author":"Biancone","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-28032013000200021","article-title":"Intestinal and extraintestinal neoplasia in patients with inflammatory bowel disease in a tertiary care hospital","volume":"50","author":"Campos","year":"2013","journal-title":"Arq. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10620-010-1430-z","article-title":"Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population","volume":"56","author":"Chiorean","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein\u2013Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"Morais","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: A Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjx040","article-title":"Cancer risk in the early stages of inflammatory bowel disease in korean patients: A nationwide population-based study","volume":"11","author":"Jung","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/00365521.2013.846402","article-title":"Malignancies in patients with inflammatory bowel disease: A nationwide register study in Finland","volume":"48","author":"Jussila","year":"2013","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","article-title":"Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"34","author":"Khan","year":"2017","journal-title":"Drugs Aging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjz204","article-title":"Lack of increased risk of lymphoma by thiopurines or biologics in japanese patients with inflammatory bowel disease: A large-scale administrative database analysis","volume":"14","author":"Kobayashi","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: A Quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(12)60954-8","article-title":"Sa1247 Low risk of lymphoma in inflammatory bowel diseases in Western Hungary. Results from a population-based incident cohort","volume":"142","author":"Lakatos","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000447259","article-title":"Malignancies in patients with inflammatory bowel disease: A single-centre experience","volume":"94","author":"Madanchi","year":"2016","journal-title":"Digestion"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000273784","article-title":"Malignancy in Crohn\u2019s disease: Incidence and clinical characteristics in Japan","volume":"81","author":"Mizushima","year":"2010","journal-title":"Digestion"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/jgh.15880","article-title":"Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India","volume":"37","author":"Ranjan","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in inflammatory bowel disease: Frequency, incidence and risk factors-results from the Swiss IBD cohort study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.30183","article-title":"Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort","volume":"139","author":"Wintjens","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gastrohep.2009.09.002","article-title":"Trastornos linfoproliferativos en una unidad de enfermedad inflamatoria intestinal [Lymphoproliferative disorders in an inflammatory bowel disease unit]","volume":"33","year":"2010","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jgh.12189","article-title":"Cancer risk in Japanese Crohn\u2019s disease patients: Investigation of the standardized incidence ratio","volume":"28","author":"Yano","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u2014What are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V14.10.1151.1151","article-title":"Leukemia and auto-immunization\u2014Some possible relationships","volume":"14","author":"Dameshek","year":"1959","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2007.06.033","article-title":"Multistep pathogenesis of autoimmune disease","volume":"130","author":"Goodnow","year":"2007","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.24141","article-title":"Autoimmunity and lymphomagenesis","volume":"124","author":"Goldin","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102945","DOI":"10.1016\/j.critrevonc.2020.102945","article-title":"Lymphoma in the setting of autoimmune diseases: A review of association and mechanisms","volume":"150","author":"Khanmohammadi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/10428199209053610","article-title":"Autoantibodies in the sera of patients with lymphoma","volume":"7","author":"Swissa","year":"1992","journal-title":"Leuk. Lymphoma"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2141.2003.04587.x","article-title":"Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin\u2019s lymphoma","volume":"123","author":"Guyomard","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2353\/ajpath.2010.100150","article-title":"Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma","volume":"177","author":"Bruneau","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fonc.2015.00051","article-title":"The Link between Autoimmunity and Lymphoma: Does NOTCH Signaling Play a Contributing Role?","volume":"5","author":"Kuksin","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1586\/eci.10.36","article-title":"Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease","volume":"6","author":"Bewtra","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_70","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_71","first-page":"51","article-title":"Extra-intestinal Hodgkin\u2019s lymphoma in a Crohn\u2019s disease patient on long-term azathioprine and infliximab therapy","volume":"31","author":"Dahhan","year":"2010","journal-title":"Trop. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: Expanding the groups at risk","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_73","first-page":"107","article-title":"Lymphoma Complicating IBD Immunomodulator Therapy: A Reminder to be Vigilant","volume":"1","author":"Sluckis","year":"2016","journal-title":"J. Gastroenterol. Complicat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s10620-014-3191-6","article-title":"Hodgkin lymphoma following adalimumab for the treatment of Crohn\u2019s disease in an adolescent","volume":"59","author":"Rodriguez","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: The b\u00eate noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MIB.0000000000000002","article-title":"Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops","volume":"20","author":"Swoger","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: Inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2174\/1389450115666140821113330","article-title":"Management of inflammatory bowel disease patients with a cancer history","volume":"15","author":"Beaugerie","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clcc.2017.06.009","article-title":"Intestinal and extraintestinal cancers associated with inflammatory bowel disease","volume":"17","author":"Chang","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4132\/KoreanJPathol.2014.48.5.387","article-title":"Pulmonary hodgkin lymphoma in a patient with Crohn\u2019s disease","volume":"48","author":"Park","year":"2014","journal-title":"Korean J. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13000-020-00954-8","article-title":"A case of iatrogenic immunodeficiency-associated colonic lymphoma complicating ulcerative colitis","volume":"15","author":"Suzuki","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clml.2011.03.018","article-title":"Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn\u2019s disease: A case report and review of the literature","volume":"11","author":"Cassaday","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-Mercaptopurine in Crohn Disease","volume":"123","author":"Pearson","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/014107688708000711","article-title":"Association between Azathioprine Therapy and Lymphoma in Rheumatoid Disease","volume":"80","author":"Pitt","year":"1987","journal-title":"J. R. Soc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4291\/wjgp.v6.i4.181","article-title":"Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders","volume":"6","author":"Lam","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients","volume":"7","author":"Chaparro","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_88","first-page":"325","article-title":"Methotrexate-associated lymphoma in patients with rheumatoid arthritis. Report of two cases","volume":"39","author":"Bachman","year":"1996","journal-title":"Am. Coll. Rheumathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2014How does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3960\/jslrt.56.165","article-title":"The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis","volume":"56","author":"Tokuhira","year":"2017","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/cas.13249","article-title":"Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types","volume":"108","author":"Gion","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein\u2013Barr virus by methotrexate: A potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: Meta-analysis of placebo-controlled trials","volume":"6","author":"Deltenre","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_94","first-page":"59","article-title":"Recent insights into the molecular pathogenesis of Crohn\u2019s disease: A review of emerging therapeutic targets","volume":"9","author":"Manuc","year":"2016","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","article-title":"The relationship between infliximab treatment and lymphoma in Crohn\u2019s disease","volume":"117","author":"Bickston","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kelsen, J., Dige, A., Schwindt, H., D\u2019Amore, F., Pedersen, F.S., Agnholt, J., Christensen, L.A., Dahlerup, J.F., and Hvas, C.L. (2011). Infliximab induces clonal expansion of \u03b3\u03b4-T cells in Crohn\u2019s disease: A predictor of lymphoma risk?. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017890"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, Azathioprine, or Combination Therapy for Crohn\u2019s Disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13256-016-1036-y","article-title":"Tofacitinib for the treatment of tumor necrosis factor-\u03b1 inhibitor refractory esophageal Crohn\u2019s disease: A case report","volume":"10","author":"Nathoo","year":"2016","journal-title":"J. Med. Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e20048","DOI":"10.1097\/MD.0000000000020048","article-title":"A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis","volume":"99","author":"Charakopoulos","year":"2020","journal-title":"Medicine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.3748\/wjg.v29.i43.5865","article-title":"Pediatric-type follicular lymphoma in a Crohn\u2019s disease patient receiving anti-\u03b14\u03b27-integrin therapy: A case report","volume":"29","author":"Yerigeri","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1756284819848631","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: Efficacy and safety from clinical trials to real-world experience","volume":"12","author":"Parigi","year":"2019","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_107","first-page":"685","article-title":"Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program","volume":"70","author":"Mariette","year":"2018","journal-title":"Am. Coll. Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: Efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_109","first-page":"265","article-title":"Long-term safety and tolerability of oral tofacitinib in patients with Crohn\u2019s disease: Results from a phase 2 open-label 48-week extension study","volume":"152","author":"Higgins","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus kinase inhibitors in inflammatory bowel disease","volume":"11","author":"Wildenberg","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e11609","DOI":"10.1097\/MD.0000000000011609","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses","volume":"97","author":"Lomonte","year":"2018","journal-title":"Medicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.gtc.2017.05.015","article-title":"Janus kinase antagonists and other novel small molecules for the treatment of Crohn\u2019s Disease","volume":"46","author":"Boland","year":"2017","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/ecco-jcc\/jjz084","article-title":"Anaplastic large cell T cell lymphoma in a patient with severe therapy-refractory Crohn\u2019s Disease on long-standing immunosuppressive medication during ustekinumab treatment: A case report and review of the literature","volume":"13","author":"Smeets","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1702621","article-title":"Crohn\u2019s disease complicated by relapsed extranodal Hodgkin\u2019s lymphoma: Prolonged complete remission after unmanipulated PBPC autotransplant","volume":"26","author":"Musso","year":"2000","journal-title":"Bone Marrow Transplant."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:26Z","timestamp":1760106386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":114,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25084241"],"URL":"https:\/\/doi.org\/10.3390\/ijms25084241","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}